Acadian Asset Management
NTGN

Acadian Asset Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Acadian Asset Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-94,908
Closed -$251K – 2408
2020
Q1 		$251K Buy
94,908
+5,953
+7% +$9.76K ﹤0.01% 1148
2019
Q4 		$105K Sell
88,955
-3,683
-4% -$5.89K ﹤0.01% 1442
2019
Q3 		$159K Buy
92,638
+50,771
+121% +$154K ﹤0.01% 1376
2019
Q2 		$199K Buy
41,867
+500
+1% +$2.8K ﹤0.01% 1229
2019
Q1 		$268K Buy
+41,367
New +$217K ﹤0.01% 1281

Acadian Asset Management's NTGN Position: Q2 2020 in Review

Acadian Asset Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 94,908 shares — an estimated $251K sold.

Acadian Asset Management first reported a position in NTGN in Q1 2019 and held it in 5 quarters. The position peaked at $268K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

  • Acadian Asset Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Acadian Asset Management sold 94,908 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $251K.
  • Acadian Asset Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
  • Acadian Asset Management's Neon Therapeutics, Inc. Common Stock position peaked at $268K in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Acadian Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.